Breakthrough in Triple-Negative Breast Cancer (TNBC)

The News:

The FDA has approved datopotamab deruxtecan-dlnk for patients with unresectable or metastatic triplenegative breast cancer who have received prior systemic therapies and are ineligible for targeted PD-1/ PD-L1 inhibitors.

Why it Matters:

TNBC remains a major clinical challenge due to the lack of estrogen, progesterone, or HER2 receptors. This TROP2-directed antibody-drug conjugate delivers a cytotoxic payload directly to target cells, providing a robust, targeted alternative to traditional systemic chemotherapies and improving progression-free survival metrics.